ACET:NSD-Adicet Bio Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.58

Change

+0.58 (+4.14)%

Market Cap

USD 0.58B

Volume

0.32M

Avg Analyst Target

USD 25.40 (+74.21%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACET Stock Forecast & Price:
Based on the Adicet Bio Inc stock forecasts from 4 analysts, the average analyst target price for Adicet Bio Inc is USD 25.40 over the next 12 months. Adicet Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adicet Bio Inc is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Adicet Bio Inc’s stock price was USD 14.58. Adicet Bio Inc’s stock price has changed by +22.83% over the past week, +24.09% over the past month and +44.07% over the last year.

About Adicet Bio Inc (ACET:NSD)

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumo ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+4.18 (+1.51%)

USD73.48B 30.32 20.19
REGN Regeneron Pharmaceuticals Inc

+3.20 (+0.54%)

USD66.17B 8.57 6.35
MRNA Moderna Inc

+0.62 (+0.44%)

USD57.82B 4.27 2.57
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.59 (+0.33%)

USD32.85B 55.02 44.86
BNTX BioNTech SE

+2.16 (+1.54%)

USD32.57B 2.40 1.28
RPRX Royalty Pharma Plc

-0.47 (-1.10%)

USD28.87B 31.29 15.41
GMAB Genmab AS

+0.32 (+1.02%)

USD21.17B 63.61 5.25
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ARGX argenx NV ADR

+9.11 (+2.50%)

USD20.26B N/A -30.89

ETFs Containing ACET

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.64% 80% B- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.64% 80% B- 57% F
Trailing 12 Months  
Capital Gain 41.69% 97% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.69% 97% A+ 97% A+
Trailing 5 Years  
Capital Gain -5.63% 69% D+ 46% F
Dividend Return 1.39% 20% F 4% F
Total Return -4.24% 69% D+ 39% F
Average Annual (5 Year Horizon)  
Capital Gain 2,194.47% 99% A+ 99% A+
Dividend Return 0.27% 9% F 8% F
Total Return 2,194.74% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 4,029.28% 1% F 1% F
Risk Adjusted Return 54.47% 91% A- 83% B
Market Capitalization 0.58B 76% C 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.60 21% F 23% F
Price/Book Ratio 1.80 50% F 45% F
Price / Cash Flow Ratio -14.04 87% B+ 80% B-
EV/EBITDA -8.79 99% A+ 98% A+
Management Effectiveness  
Return on Equity -13.18% 88% B+ 39% F
Return on Invested Capital -147.09% 12% F 8% F
Return on Assets -7.15% 89% B+ 34% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.24 36% F 21% F
Short Percent 19.69% 6% F 8% F
Beta 2.01 18% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector